Catalog No.
Product Name
Application
Product Information
Citations
-
Stat3 Inhibitor
S3I-201 (NSC 74859) is a novel inhibitor of Stat3 that inhibits Stat3, Stat3 complex formation and Stat3-DNA binding activity in vitro (IC50 = 86 ?? 33 μM) and Stat3-dependent transcriptional activities.- Bae WJ, .et al. , J Exp Clin Cancer Res, 2019, 38:484 PMID: 31805999
- Ethan L. Morgan, .et al. , PLoS Pathog, 2018, Apr; 14(4): e1006975 PMID: 29630659
- Nishimura K, .et al. , Biochem Biophys Res Commun, 2018, Jan 1;495(1):1317-1321 PMID: 29191652
- Soleimani AH, .et al. , Drug Deliv Transl Res, 2017, Aug;7(4):571-581 PMID: 28290050
-
STAT inhibitor
Fludarabine or fludarabine phosphate (Fludara) is a chemotherapy drug used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas) .Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. It is active against both dividing and resting cells.- Irene Dell'Anno, .et al. , Invest New Drugs, 2020, Dec 9 PMID: 33300108
-
STAT3 inhibitor
STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis.- Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
- Rongshou Wu, .et al. , Sci Rep, 2023, 13: 16998 PMID: 37813900
-
Pdia3/ERp57 activator, STAT3 inhibitor
Diosgenin is a steroid sapogenin and the precursor for the semisynthesis of progesterone which in turn was used in early combined oral contraceptive pills.It is the product of hydrolysis by acids, strong bases, or enzymes of saponins, extracted from the tubers of Dioscorea wild yam, such as the Kokoro.- Rashmi Rawat, .et al. , Food Chemistry Advances, 2022, 1: 100092
-
STAT3 inhibitor
Stattic is a small molecule shown to selectively inhibit the activation of the Stat3 transcription factor by blocking phosphorylation and dimerization events.- Siu Hong Dexter Wong, .et al. , Sci Adv, 2023, Jul 7;9(27):eadg9593 PMID: 37418519
-
Pdia3/ERp57 activator, STAT3 inhibitor
Diosgenin glucoside, a saponin compound extracted from Tritulus terrestris L., provides neuroprotection by regulating microglial M1 polarization. Diosgenin glucoside protects against spinal cord injury by regulating autophagy and alleviating apoptosis . -
multi-kinase inhibitor
Cenisertib (AS-703569) is a multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. -
multi-kinase inhibitor
Lestaurtinib (CEP-701;KT-5555) is a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits JAK2, FLT3 and TrkA with IC50s of 0.9, 3 and less than 25 nM, respectively. -
STAT inhibitor
Napabucasin is an orally-administered small molecule which can block cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells. -
STAT Inhibitor
STAT5 Inhibitor is a cell-permeable, nonpetidic nicotinoyl hydrazone that suppresses STAT5 by targeting its SH2 domain (IC50 = 47 μM against STAT5?? SH2 domain EPO peptide binding activity). -
Stat3 inhibitor & Apoptosis inducer
Homoharringtonine is a cephalotaxine alkaloid which inhibits the formation of diphenylalanine and acetylphenylalanyl-puromycin in liver ribosomes. -
STAT inhibitor
Nifuroxazide is an inhibitor of STAT activation and signaling activity, is an oral nitrofuran antibiotic, used to treat colitis and diarrhea in humans and non-humans. -
STAT6 inhibitor
AS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM. -
STAT3 inhibitor
inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties. -
STAT5 inhibitor
STAT5-IN-2 is a STAT5 inhibitor with EC50s of 9 μM and 5 μM in K562 and KU812 cells, respectively. Potent antileukemic effect. -
JAK2/STAT3 inhibitor
Protosappanin A is an immunosuppressive ingredient of the medicinal herb Caesalpinia sappan L. -
STAT inhibitor
Nitidine chloride, a natural benzophenanthridine alkaloid, has been shown to inhibit cancer growth via induction of cell apoptosis and suppression of cancer angiogenesis. -
JAK2/STAT3 inhibitor
Cucurbitacin I, Cucumis sativus L. has been found to suppress levels of phosphotyrosine Stat3 (signal transducer and activator of transcription 3) in v-Src-transformed NIH 3T3 cells. -
STAT3 inhibitor
Corylifol A is a phenolic compounds isolated from Psoralea corylifolia; inhibits IL-6-induced STAT3 activation and phosphorylation(IC50=0.8 uM). - Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
-
anti-inflammatory agent
Balsalazide is an anti-inflammatory agent for treatment of Inflammatory Bowel Disease. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. -
STAT3 inhibitor
STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3). -
Stat5a/b Inhibitor
IST5-002 is a selective inhibitor of Stat5a and Stat5b, with IC50 values of 1.5 μM and 3.5 μM, respectively. This compound effectively disrupts the transcriptional activity of Stat5 proteins, inducing apoptosis in prostate cancer and chronic myeloid leukemia (CML) cells. IST5-002 is suitable for research applications focused on understanding the role of Stat5 in cancer progression and therapeutic targeting in prostate cancer and CML. -
STAT3 Inhibitor
Danvatirsen is an antisense oligonucleotide that specifically inhibits STAT3, a transcription factor involved in cell survival and proliferation. This compound reduces cell viability and promotes apoptosis in leukemia cell lines, while downregulating the expression of endogenous STAT3 and its downstream target genes. Additionally, Danvatirsen effectively diminishes proliferation and tumorigenicity in models of neuroblastoma and lymphoma. In vivo studies demonstrate its capacity to inhibit tumor growth rates in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer. Danvatirsen is applicable in research focused on lymphoma, myelodysplastic syndrome, acute myeloid leukemia, and neuroblastoma. -
STAT3 Inhibitor
HP590 is a potent, orally active inhibitor of STAT3, demonstrating an IC50 of 27.8 nM for STAT3 luciferase activity and 24.7 nM for ATP inhibition. This compound exhibits significant anti-proliferative effects on gastric cancer cells and effectively induces apoptosis. HP590 serves as a valuable research tool for investigating the role of STAT3 in cancer biology and potential therapeutic interventions. -
STAT3 Signal Inhibitor
STAT3-IN-12 is a potent inhibitor of the STAT3 signaling pathway, effectively blocking IL-6 induced JAK/STAT3 activation. This compound exhibits significant anti-cancer activity by inhibiting cell growth, reducing migration, promoting apoptosis, and inducing cell cycle arrest. STAT3-IN-12 is particularly relevant for research applications in cancers such as hepatocellular carcinoma (HCC) and esophageal carcinoma. -
STAT3 Phosphorylation Inhibitor
Tetramethylcurcumin is a selective inhibitor of STAT3 phosphorylation, targeting Janus kinase 2 and the Src homology-2 domain of STAT3. This compound demonstrates significant anti-inflammatory and anti-cancer properties, making it a valuable tool for research into cancer biology and inflammatory pathways. Its ability to modulate key signaling events provides insight into therapeutic strategies for diseases driven by aberrant STAT3 activity. -
STAT3 Inhibitor
STAT3-IN-11 is a selective inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3), specifically targeting the phosphorylation at Tyr705. This compound downregulates the phosphorylation of downstream genes such as Survivin and Mcl-1, while leaving upstream tyrosine kinases like Src and JAK2 unaffected. By inducing apoptosis in cancer cells, STAT3-IN-11 presents potential as a valuable tool for research in cancer therapeutics and the development of effective STAT3 inhibitors. -
AKR1C1/JAK2/STAT3/NF-κB Inhibitor
Zingiberen Newsaponin is a potent inhibitor of the AKR1C1/JAK2/STAT3 and NF-κB signaling pathways. This steroid saponin compound demonstrates significant anti-hepatocellular carcinoma (HCC) activity by promoting cancer cell apoptosis through the induction of oxidative stress, as evidenced by the upregulation of ROS and MDA levels. Additionally, Zingiberen Newsaponin mitigates cerebral ischemia-reperfusion injury by reducing pro-inflammatory cytokines and enhancing superoxide dismutase (SOD) activity, thereby protecting neuronal cells. Furthermore, it has been shown to induce platelet aggregation, broadening its application in cardiovascular research. -
STAT3-SH2 Domain Inhibitor
STAT3-SH2 Domain Inhibitor 1 specifically targets the Src Homology 2 (SH2) domain of STAT3, exhibiting a Kd value of 1.57 μM. This compound effectively inhibits STAT3 signaling and transcriptional activation, leading to apoptosis in gastric cancer cells. It serves as a valuable tool for researching mechanisms of cancer progression and potential therapeutic strategies targeting the STAT3 pathway. -
STAT3 Inhibitor
8-Epixanthatin is a STAT3 inhibitor derived from Xanthium chinese Mill. It effectively inhibits STAT3 activation, leading to the induction of apoptosis in cancer cells. This compound demonstrates notable anti-tumor activity, making it a valuable tool for research applications focused on cancer biology and therapeutic development. -
STAT3 Inhibitor
WB436B is a selective inhibitor of STAT3, targeting STAT3-Tyr705 phosphorylation and modulating the expression of downstream STAT3 target genes. This compound exhibits significant cytotoxicity against pancreatic cancer cells while promoting apoptosis. In preclinical mouse models, WB436B has been shown to suppress tumor growth and metastasis, leading to an extended survival rate in tumor-bearing subjects. This makes WB436B a valuable tool for research in cancer biology and therapeutic development. -
STAT3 Inhibitor
HJC0416 hydrochloride is a potent inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that exhibits enhanced anticancer properties compared to Stattic. This compound has demonstrated significant biological activity against breast cancer, making it a promising candidate for cancer research applications. Its oral bioavailability and efficacy highlight its potential as a valuable tool for investigating STAT3-related pathways in oncology. -
STAT3 Inhibitor
SC99 is a selective inhibitor of the STAT3 pathway, exerting its effects through the inhibition of JAK2. By binding to the ATP-binding pocket of JAK2, SC99 effectively prevents the phosphorylation of both JAK2 and STAT3, while sparing other kinases linked to STAT3 signaling. SC99 demonstrates significant biological activity, including the inhibition of platelet activation and aggregation, as well as potent anti-myeloma and anti-thrombotic effects, making it a valuable tool for research in cancer and cardiovascular studies. -
STAT3 Inhibitor
LLL3 is a potent STAT3 inhibitor that effectively impedes the dimerization and phosphorylation of STAT3, thereby blocking its translocation into the nucleus. This mechanism leads to reduced expression of STAT3-dependent genes, including those encoding Bcl-xL and cyclin D1. Moreover, LLL3 has been shown to induce growth inhibition and apoptosis in human breast cancer and rhabdomyosarcoma cells through the activation of the caspase pathway. This reagent is valuable for investigating cancers associated with persistent STAT3 activation. -
STAT5b Inhibitor
Pomstafib-2 is a potent and selective inhibitor of STAT5b, a transcription factor involved in various signaling pathways. This compound reduces the expression of phosphorylated STAT5b (pSTAT5b) and promotes apoptotic processes in cells. Pomstafib-2 is valuable for studying STAT5b-related biological functions and developing therapies targeting STAT5b-driven malignancies. -
STAT1 Enhancer
2-Nitrophenol (2-NP) is a selective enhancer of STAT1 transcription, acting primarily through modulation of interferon signaling pathways. This compound has been shown to augment the ability of IFN-γ to inhibit cell proliferation in human breast cancer and fibrosarcoma models. Its application in research focuses on elucidating the mechanisms of STAT1-related pathways and developing potential therapeutic strategies for cancer treatment.
